YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC-Reference-Cited by-同舟云学术

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Published:2017-12 Issue:12 Volume:19 Page:1012-1021
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Ghiso Elena,Migliore Cristina,Ciciriello Vito,Morando Elena,Petrelli Annalisa,Corso Simona,De Luca Emmanuele,Gatti Gaia,Volante Marco,Giordano Silvia

Publisher

Elsevier BV

Subject

Cancer Research

Reference36 articles.

1. Cancer drug resistance: an evolving paradigm;Holohan;Nat Rev Cancer,2013

2. Circumventing cancer drug resistance in the era of personalized medicine;Garraway;Cancer Discov,2012

3. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Med,2005

4. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR;Bell;Nat Genet,2005

5. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling;Engelman;Science,2007

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of Tumor Microenvironment through YAP/TAZ under Tumor Hypoxia;Cancers;2024-08-30

2. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk;Gene;2024-07

3. Natural compounds targeting YAP/TAZ axis in cancer: Current state of art and challenges;Pharmacological Research;2024-05

4. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells;Cancer Letters;2024-04

5. Hippo Signaling at the Hallmarks of Cancer and Drug Resistance;Cells;2024-03-22